加载中
NASDAQHealthcareMedical - Instruments & Supplies
最新数据
US$172.51
−US$1.37 · -0.79%
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.
收盘时
US$172.51
−US$1.37 · -0.79%
盘后
US$172.51
US$0.00 · 0.00%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.
日内区间
当前US$172.51
52周区间
当前US$172.51
盘中时间采用ET。市场数据可能有所延迟。
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.
日内区间
当前US$172.51
52周区间
当前US$172.51
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 7.38亿 USD | 6.34亿 USD | 6.32亿 USD | 8.02亿 USD | 6.71亿 USD |
| 销货成本 | 3.91亿 USD | 3.6亿 USD | 3.54亿 USD | 3.46亿 USD | 2.79亿 USD |
| 毛利 | 3.48亿 USD | 2.75亿 USD | 2.78亿 USD | 4.56亿 USD | 3.91亿 USD |
| 研究与开发 | 5417.7万 USD | 4320万 USD | 4272.2万 USD | 4393.6万 USD | 3427.4万 USD |
| 销售、一般及管理费用 | 2.91亿 USD | 2.63亿 USD | 2.19亿 USD | 2.16亿 USD | 1.84亿 USD |
| 营业费用 | 2.88亿 USD | 3.1亿 USD | 2.31亿 USD | 2.31亿 USD | 2.24亿 USD |
| 利息收入 | 2757.4万 USD | — | — | 697.8万 USD | 17.6万 USD |
| 利息支出 | 2317.3万 USD | 2257.4万 USD | 1002.6万 USD | 297.7万 USD | 1271.4万 USD |
| 折旧和摊销 | 9695.6万 USD | 8656.2万 USD | 8611.4万 USD | 5701.2万 USD | 3844.7万 USD |
| 营业利润 | 5957.8万 USD | −3511.4万 USD | 4770.3万 USD | 2.25亿 USD | 1.67亿 USD |
| 净利润 | 4889.4万 USD | −2551.4万 USD | 3559.6万 USD | 1.86亿 USD | 1.28亿 USD |
公司数据更新于 2026年10月12日。
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI3.08亿0.01%2.3万亿 USD0.03%US$381.57-0.10%
Vanguard Morningstar Small-Cap ETFVB2.23亿0.12%1853亿 USD0.03%US$288.16-0.46%
Vanguard Morningstar Small-Cap Growth ETFVBK1.28亿0.28%447亿 USD0.05%US$340.88-1.12%
Vanguard Extended Market ETFVXF1.12亿0.11%954亿 USD0.05%US$233.52-0.63%
First Trust NYSE Arca Biotechnology Index FundFBT1.09亿3.77%28.91亿 USD0.55%US$263.9-0.57%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY8152.38万0.32%258.17亿 USD0.23%US$667.3-0.38%
Dimensional - US Small Cap ETFDFAS7828.58万0.23%338.69亿 USD0.31%US$78.17-0.23%
iShares Biotechnology ETFIBB7195.88万0.66%108.2亿 USD0.44%US$204.26-1.08%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFFirst Trust NYSE Arca Biotechnology Index FundFBTState Street SPDR S&P MIDCAP 400 ETF TrustMDYDimensional - US Small Cap ETFDFASiShares Biotechnology ETFIBBAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
